Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

The US Speaker of the House Vows Congress will Vote on the Biosecure Act in 2024

publication date: Jul 9, 2024

The Biosecure Act is back in the news following a speech given yesterday by the Speaker of the House, Mike Johnson, who vowed to pass the bill before the end of the year. The Biosecure Bill prohibits US pharmaceutical companies from doing business with China-based CROs, especially WuXi AppTec, but including other China CROs as well. The legislation is designed to prevent the CROs from passing on information about drugs under development by US companies at the CROs and also from forwarding genetic information about US citizens who participated in clinical trials. Speaker Johnson also plans to stop US investment in China. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital